Tocilizumab

A4DAB271 | Immune-mediated / inflammatory disorders | Approved
IL6R/CD126
G1 / IgG1
Assistance Publique Hopitaux de Paris Charite - Universitatsmedizin Berlin Chugai Pharmaceutical Hospital for Special Surgery JW Pharmaceutical Roche University Hospital Inselspital University Hospital Osaka University Tubingen University of Bern University of Pittsburgh
Approved
Whole mAb
Atlizumab R-1569 R1569 R 1569 RG-1569 RG1569 RG 1569 RO4877533 RO-4877533 RO 4877533 RoActemra
6.5
IMGT PubChem (104253153) PubChem (135345962) PubChem (178103463) PubChem (329976997) PubChem (347910344) PubChem (349016747) PubChem (354355060) PubChem (385326041) PubChem (385327557) PubChem (387061215) PubChem (405092064) PubChem (469690931) PubChem (472264665) PubChem (472385906) PubChem (475546922) PubChem (481155381) PubChem (485726264) PubChem (488425338) PubChem (496156075) PubChem (498137477) PubChem (508644835) PubChem (513262009) PubChem (517913830) PubChem (519973228) Thera-SAbDab YAbS
Avg A4D Score
-0.6933
Score Range
-0.69
Structures
1
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB271_8j6f_H_L 8j6f 100% -0.6933 6.5 4.0 -0.3217 -0.739